The Lilabean Foundation for Pediatric Brain Cancer Research Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2020
NCT04485559
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

The Lilabean Foundation for Pediatric Brain Cancer Research

Active Ingredients

Drugs in Phase 1 Trials (2)

everolimus (zortress) (1 trial)

trametinib (mekinist) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2